scholarly journals Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome

Nutrients ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1635 ◽  
Author(s):  
Dale ◽  
Jensen ◽  
Hausken ◽  
Valeur ◽  
Hoff ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Placebo Group ◽  
Symptom Severity ◽  
Protein Hydrolysate ◽  
Short Chain Fatty Acids ◽  
Fecal Calprotectin ◽  
Serum Markers ◽  
Gut Health ◽  
Double Blind ◽  
Irritable Bowel

Peptides from fish may beneficially affect several metabolic outcomes, including gut health and inflammation. The effect of fish peptides in subjects with irritable bowel syndrome (IBS) has not previously been investigated, hence this study aimed to evaluate the effect of a cod protein hydrolysate (CPH) supplement on symptom severity, gut integrity markers and fecal fermentation in IBS-patients. A double-blind, randomized parallel-intervention with six weeks of supplementation with 2.5 g CPH (n = 13) or placebo (n = 15) was conducted. The outcomes were evaluated at baseline and the end of the study. The primary outcomes were symptom severity evaluated by the IBS severity scoring system (IBS-SSS) and quality of life. The secondary outcomes included gut integrity markers and pro-inflammatory cytokines in serum, fecal fermentation measured by concentration of short-chain fatty acids (SCFAs) and fecal calprotectin. The groups were comparable at baseline. The total IBS-SSS-scores were reduced in both the CPH-group (298 ± 69 to 236 ± 106, p = 0.081) and the placebo-group (295 ± 107 to 202 ± 103, p = 0.005), but the end of study-scores did not differ (p = 0.395). The concentrations of serum markers and SCFAs did not change for any of the groups. The baseline measures for the whole group showed that the total SCFA concentrations were inversely correlated with the total IBS-SSS-score (r = −0.527, p = 0.004). Our study showed that a low dose of CPH taken daily by IBS-patients for six weeks did not affect symptom severity, gut integrity markers or fecal fermentation when compared to the placebo group.

scholarly journals The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 756
Author(s):  
Barbara Skrzydło-Radomańska ◽  
Beata Prozorow-Król ◽  
Halina Cichoż-Lach ◽  
Emilia Majsiak ◽  
Joanna Beata Bierła ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Placebo Group ◽  
Symptom Severity ◽  
Study Groups ◽  
Controlled Study ◽  
Double Blind ◽  
Global Improvement ◽  
Probiotic Group ◽  
Probiotic Preparation ◽  
Irritable Bowel

The aim of this randomized double-blind placebo-controlled study was to evaluate the effectiveness and safety of multi-strain probiotic in adults with diarrhea-predominant irritable bowel syndrome (IBS-D). The patients were randomized to receive a mixture of Lactobacillus, Bifidobacterium, and Streptococcus thermophilus strains or placebo for eight weeks. Primary endpoints included changes in symptom severity and improvement assessed with the IBS Severity Scoring System (IBS-SSS) and Global Improvement Scale (IBS-GIS). The probiotic in comparison with placebo significantly improved the IBS symptom severity (the change of total IBS-SSS score from baseline −165.8 ± 78.9 in the probiotic group and −105.6 ± 60.2 in the placebo group, p = 0.005) and in the specific scores related to the severity of pain (p = 0.015) and the quality of life (p = 0.016) after eight weeks of intervention. The probiotic group indicated an improvement in symptoms with the use of the IBS-GIS compared with the placebo group after four (p = 0.04) and eight weeks (p = 0.003). The occurrence of adverse events did not differ between study groups. In conclusion, the multi-strain probiotic intervention resulted in a significant improvement in IBS symptoms evaluated with the use of both IBS-SSS and IBS-GIS scales. The results suggest that the studied probiotic preparation is well tolerated and safe and can offer benefits for patients with IBS-D. (registration number in Clinicaltrials.gov NCT 04662957).

scholarly journals How to improve effectiveness of treatment of patients with irritable bowel syndrome?

2021 ◽  
pp. 134-140
Author(s):  
E. V. Golovanova
Keyword(s):  
Irritable Bowel Syndrome ◽  
Intestinal Microbiota ◽  
Symptom Severity ◽  
Clinical Symptoms ◽  
Functional Gastrointestinal Disorders ◽  
Gastrointestinal Diseases ◽  
Controlled Study ◽  
Bacterial Strains ◽  
Double Blind ◽  
Irritable Bowel

This article discusses ways to improve the effectiveness of treatment of irritable bowel syndrome (IBS), one of the most common functional gastrointestinal disorders (FGID). The significance of this issue is caused by high frequency of pathology detection among the young employable population and the difficulties in choosing an effective treatment that relieves not only the symptom severity, but also the frequency of relapses. Inadequate therapy reduces patients’ compliance with treatment and significantly worsens their quality of life. The choice of a drug that fails to provide a positive effect on all factors that form the pain syndrome is the most common reason for ineffective treatment. In addition, the measures aimed at managing such pathogenic factors as intestinal microbiota dysbiosis are often not taken. Meanwhile, numerous studies have shown that the intestinal microbiota imbalance is accompanied by increased intestinal permeability, which leads to the penetration of aggressive agents through extended intercellular spaces. This is accompanied by the occurrence of subclinical inflammation in the submucosal layer, which results in impaired motor function and increased visceral sensitivity. Thus, the intestinal microflora imbalance is one of the most important factors that form clinical symptoms of IBS. The article substantiates the advantages of using trimebutin, a gastrointestinal tract motility regulator, in functional gastrointestinal diseases from the standpoint of evidence-based medicine. The modern scientific knowledge on the  effectiveness of  microbiota  adjustment in  alleviating IBS symptoms is presented. In  particular, the  double-blind, placebo-controlled study has shown the efficacy of a multi-strain probiotic complex in relieving clinical symptom severity of IBS. The optimal treatment regimen for a patient with IBS should include a drug regulating the gastrointestinal motility and reducing visceral hypersensitivity and a probiotic complex containing bacterial strains that have proved their efficacy in this group of patients. 

scholarly journals Efficacy of probiotics in irritable bowel syndrome: A randomized, double blind placebo-controlled study

2016 ◽  
Vol 6 (1) ◽  
pp. 21 ◽  
Author(s):  
Md. Zahidur Rahman ◽  
Mohammad Shoaib Chowdhury ◽  
Mohammad Asadur Rahman ◽  
Shohely Parveen ◽  
Rajib Barua ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Placebo Group ◽  
Intestinal Microbiota ◽  
Therapeutic Potential ◽  
Intestinal Barrier ◽  
Controlled Study ◽  
Double Blind ◽  
Before And After ◽  
Irritable Bowel

<p><strong>Background:</strong> Gut flora have important trophic effects on intestinal epithelia and on immune structure and fonction.They also protect colonized host against invasion by alien microbes.Recent research suggests that an imbalance of the intestinal microbiota and a dysfunctional intestinal barrier might trigger irritable bowel syndrome (lBS). As probiotics have been reported to restore the intestinal microbiota and the gut barrier, the therapeutic potential of probiotics within IBS became of strong interest. <strong></strong></p><p><strong>Objectives: </strong>To assess the efficacy of probiotics in lBS. <strong></strong></p><p><strong>Methods: </strong>Patients of 15 to 60 years old and both sexes were included f om the out patient department (OPD) of gastroenterology, Bangabandhu Sheikh Mujib Medi­cal University (BSMMU). A validated lBS-QOL instmment consisted of 34 questions used to assess improvement of quality of Iife before and after treatment. A total of 65 diarrhoea predominant LBS patients were randomised to receive either probiotics(n-33) or placebo(n-32) twice daily frir 6 weeks.</p><p><strong>Results:</strong> At the end of 6 weeks therapy, improvement in various symptoms(abclominal pain, stool frequency, consistency and 11atulence) in probiotics group was statistically significant. Mean QOL score before treatment was 103 in probiotics group and I 06 in placebo group. After 6 weeks of treatment mean QOL score was 82 in probiotics group and I 02.58 in placebo group. No side effects of the therapeutic agents were observed in any patient during the trial. <strong></strong></p><p><strong>Conclusions:</strong> Probiotics effectively alleviates global IBS and improves TBS symptoms simultaneously with an improvement of quality of life.</p>

Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study

2018 ◽  
Vol 9 (4) ◽  
pp. 563-572 ◽  
Author(s):  
M. Ratna Sudha ◽  
N. Jayanthi ◽  
M. Aasin ◽  
R.D. Dhanashri ◽  
T. Anirudh
Keyword(s):  
Irritable Bowel Syndrome ◽  
Placebo Group ◽  
Pain Intensity ◽  
Bacillus Coagulans ◽  
Treated Group ◽  
Abdominal Discomfort ◽  
Bowel Habit ◽  
Age Group ◽  
Double Blind ◽  
Irritable Bowel

The efficacy of the probiotic strain, Bacillus coagulans Unique IS2 in the treatment of Irritable Bowel Syndrome (IBS) was evaluated in children. A total of 141 children of either sex in the age group 4-12 years, diagnosed with IBS according to the Rome III criteria, participated in the double-blind randomised controlled trial. Children received either B. coagulans Unique IS2 chewable tablets or placebo once daily for eight weeks followed by a two week follow-up period. Reduction in pain intensity as well as other symptoms associated with Irritable Bowel Syndrome like abdominal discomfort, bloating, distension, sense of incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucus, and bowel habit satisfaction were assessed. B. coagulans Unique IS2 treated group showed a greater reduction in pain scores as evaluated by a weekly pain intensity scale. There was a significant reduction (P<0.0001) in pain intensity in the probiotic treated group (7.6±0.98) as compared to the placebo group (4.2±1.41) by the end of the treatment period (8 weeks). There was also a significant improvement in stool consistency as well as reduction in abdominal discomfort, bloating, staining, urgency, incomplete evacuation and passage of gas. Bowel habit satisfaction and global assessment of relief was also observed in the B. coagulans Unique IS2 treated group as compared to the placebo group. This study demonstrates the efficacy of B. coagulans Unique IS2 in reducing the symptoms of Irritable Bowel Syndrome in children in the age group of 4-12 years.

A Pilot Study of the Effect of Aloe barbadensis Mill. Extract (AVH200®) in Patients with Irritable Bowel Syndrome: a Randomized, Double-Blind, Placebo-Controlled Study

2015 ◽  
Vol 24 (3) ◽  
pp. 275-280 ◽  
Author(s):  
Stine Størsrud ◽  
Irina Pontén ◽  
Magnus Simrén
Keyword(s):  
Irritable Bowel Syndrome ◽  
Placebo Group ◽  
Pilot Study ◽  
Aloe Vera ◽  
Gastrointestinal Symptoms ◽  
Controlled Study ◽  
Aloe Barbadensis ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Irritable Bowel

Background & Aims: Few effective treatment options exist for patients with irritable bowel syndrome (IBS), and many patients state the use of aloe vera products reduce their symptoms. The aim of this pilot study was to investigate the effect of Aloe barbadensis Mill. Extract (AVH200®) in adult patients with IBS in a randomized, double-blind, placebo controlled study. Methods: Sixty-eight adult patients diagnosed with IBS according to the Rome III criteria were randomized to receive AVH200® or matching placebo for four weeks. Symptom questionnaires were completed on a weekly basis and the patients were asked if they had had adequate relief of their gastrointestinal symptoms. Results: A tendency towards a higher proportion of responders in the aloe vera group (55%) vs. placebo (31%), (p=0.09) was observed, and the proportion of subjects who reported adequate relief at least 50% of the weeks during the treatment period tended to be larger in the aloe vera vs. placebo group (33% vs. 14%; p=0.12). The overall severity of the gastrointestinal symptoms was reduced in the aloe vera group (314±83 vs. 257±107; p=0.003) but not the placebo group (276±88 vs. 253±100; NS), without difference between the groups (p=0.10). AVH200® was well tolerated and no serious adverse events were observed. Conclusion: Even though the primary endpoint was not met, AVH200® seems to be a promising treatment option for patients with IBS owing to the positive results seen within the secondary endpoints. This study may have been underpowered to detect a clinically meaningful difference between the treatment groups, and therefore larger randomized, controlled studies are required to confirm these results and to elucidate potential mechanisms explaining its effect.

Sign in / Sign up

Export Citation Format

Share Document